Grand Pharmaceutical (00512) completes the enrollment and dosing of all patients in the Phase III clinical trial of innovative radiolabeled drug TLX591-CDx in China and plans to submit a marketing application within this year.

Wisdom Finance APP News, Yunda Pharmaceutical (00512) announced that the group's innovative investigational radiopharmaceutical drug (RDC) TLX591-CDx (Illuccix, gallium Ga 68 PSMA-11) for the diagnosis of prostate cancer has completed all patient dosing in Phase III clinical trials conducted in China. It is planned to submit a new drug marketing application in China this year, marking another important research and development milestone in the group's field of nuclear medicine for anti-tumor diagnosis and treatment.